Dual-specificity phosphatases as molecular targets for inhibition in human disease

Antioxidants and Redox Signaling

Volumn 20, Issue 14, 2014, Pages 2251-2273

  Ríos, Pablo ^a   Nunes Xavier, Caroline E ^b   Tabernero, Lydia ^c   Köhn, Maja ^a   Pulido, Rafael ^b,d  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d BASQUE FOUNDATION FOR SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE; BR 1; CG 707; DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY PHOSPHATASE INHIBITOR; EMODIN; ENZYME INHIBITOR; GINKGETIN; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; PENTAMIDINE; PRL3 INHIBITOR 1; RHODANINE; THIENOPYRIDONE; UNCLASSIFIED DRUG;

DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; HUMAN; NEOPLASM; PRIORITY JOURNAL; REVIEW; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; SEQUENCE ALIGNMENT; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; DUAL-SPECIFICITY PHOSPHATASES; ENZYME INHIBITORS; HUMANS; MOLECULAR STRUCTURE; MOLECULAR TARGETED THERAPY; NEOPLASMS; SEQUENCE ALIGNMENT; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84898657084     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5709     Document Type: Review

References (207)

1. Adhikari D, Gorre N, Risal S, Zhao Z, Zhang H, Shen Y, and Liu K. The safe use of a PTEN inhibitor for the activation of dormant mouse primordial follicles and generation of fertilizable eggs. PLoS One 7: e39034, 2012.
2. Ahn JH, Kim SJ, Park WS, Cho SY, Ha JD, Kim SS, Kang SK, Jeong DG, Jung SK, Lee SH, Kim HM, Park SK, Lee KH, Lee CW, Ryu SE, and Choi JK. Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorg Med Chem Lett 16: 2996-2999, 2006.
3. Al-Aidaroos AQ, Yuen HF, Guo K, Zhang SD, Chung TH, Chng WJ, and Zeng Q. Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest 123: 3459-3471, 2013.
4. Al-Aidaroos AQ and Zeng Q. PRL-3 phosphatase and cancer metastasis. J Cell Biochem 111: 1087-1098, 2010.
5. Al-Mutairi M, Al-Harthi S, Cadalbert L, and Plevin R. Over-expression of mitogen-activated protein kinase phosphatase-2 enhances adhesion molecule expression and protects against apoptosis in human endothelial cells. Br J Pharmacol 161: 782-798, 2010.
6. Al-Mutairi MS, Cadalbert LC, McGachy HA, Shweash M, Schroeder J, Kurnik M, Sloss CM, Bryant CE, Alexander J, and Plevin R. MAP kinase phosphatase-2 plays a critical role in response to infection by Leishmania mexicana. PLoS Pathog 6: e1001192, 2010.
7. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, and Mustelin T. Protein tyrosine phosphatases in the human genome. Cell 117: 699-711, 2004.
8. Andersen JN, Mortensen OH, Peters GH, Drake PG, Iversen LF, Olsen OH, Jansen PG, Andersen HS, Tonks NK, and Moller NP. Structural and evolutionary relationships among protein tyrosine phosphatase domains. Mol Cell Biol 21: 7117-7136, 2001.
9. Arnoldussen YJ, Lorenzo PI, Pretorius ME, Waehre H, Risberg B, Maelandsmo GM, Danielsen HE, and Saatcioglu F. The mitogen-activated protein kinase phosphatase vaccinia H1-related protein inhibits apoptosis in prostate cancer cells and is overexpressed in prostate cancer. Cancer Res 68: 9255-9264, 2008.
10. Arora D, Köthe S, van den Eijnden M, Hooft van Huijsduijnen R, Heidel F, Fischer T, Scholl S, Tolle B, Böhmer SA, Lennartsson J, Isken F, Müller-Tidow C, and Böhmer FD. Expression of protein-tyrosine phosphatases in Acute myeloid leukemia cells: FLT3 ITD sustains high levels of DUSP6 expression. Cell Commun Signal 10: 19, 2012.
11. Auger-Messier M, Accornero F, Goonasekera SA, Bueno OF, Lorenz JN, van Berlo JH, Willette RN, and Molkentin JD. Unrestrained p38 MAPK activation in Dusp1/4 double-null mice induces cardiomyopathy. Circ Res 112: 48-56, 2013.
12. Bai L, Yoon SO, King PD, and Merchant JL. ZBP-89-induced apoptosis is p53-independent and requires JNK. Cell Death Differ 11: 663-673, 2004.
13. Bakan A, Lazo JS, Wipf P, Brummond KM, and Bahar I. Toward a molecular understanding of the interaction of dual specificity phosphatases with substrates: insights from structure-based modeling and high throughput screening. Curr Med Chem 15: 2536-2544, 2008.
14. Balko JM, Cook RS, Vaught DB, Kuba MG, Miller TW, Bhola NE, Sanders ME, Granja-Ingram NM, Smith JJ, Meszoely IM, Salter J, Dowsett M, Stemke-Hale K, González-Angulo AM, Mills GB, Pinto JA, Gómez HL, and Arteaga CL. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med 18: 1052-1059, 2012.
15. Basak S, Jacobs SB, Krieg AJ, Pathak N, Zeng Q, Kaldis P, Giaccia AJ, and Attardi LD. The metastasis-associated gene Prl-3 is a p53 target involved in cell-cycle regulation. Mol Cell 30: 303-314, 2008.
16. Bazuine M, Carlotti F, Tafrechi RS, Hoeben RC, and Maassen JA. Mitogen-activated protein kinase (MAPK) phosphatase-1 and-4 attenuate p38 MAPK during dexamethasone-induced insulin resistance in 3T3-L1 adipocytes. Mol Endocrinol 18: 1697-1707, 2004.
17. Berasi SP, Huard C, Li D, Shih HH, Sun Y, Zhong W, Paulsen JE, Brown EL, Gimeno RE, and Martinez RV. Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase. J Biol Chem 281: 27167-27177, 2006.
18. Bermudez O, Jouandin P, Rottier J, Bourcier C, Pàges G, and Gimond C. Post-transcriptional regulation of the DUSP6/MKP-3 phosphatase by MEK/ERK signaling and hypoxia. J Cell Physiol 226: 276-284, 2011.
19. Bermudez O, Pàges G, and Gimond C. The dual-specificity MAP kinase phosphatases: critical roles in development and cancer. Am J Physiol Cell Physiol 299: C189-C202, 2010.
20. Bessette DC, Qiu D, and Pallen CJ. PRL PTPs: mediators and markers of cancer progression. Cancer Metastasis Rev 27: 231-252, 2008.
21. Boschert U, Muda M, Camps M, Dickinson R, and Arkinstall S. Induction of the dual specificity phosphatase PAC1 in rat brain following seizure activity. Neuroreport 8: 3077-3080, 1997.
22. Boutros T, Chevet E, and Metrakos P. Mitogen-activated protein (MAP) kinase/MAP kinase phosphatase regulation: roles in cell growth, death, and cancer. Pharmacol Rev 60: 261-310, 2008.
23. Brion L, Maloberti PM, Gomez NV, Poderoso C, Gorostizaga AB, Mori Sequeiros Garcia MM, Acquier AB, Cooke M, Mendez CF, Podesta EJ, and Paz C. MAPK phosphatase-1 (MKP-1) expression is up-regulated by hCG/cAMP and modulates steroidogenesis in MA-10 Leydig cells. Endocrinology 152: 2665-2677, 2011.
24. Brooks WW, Shen SS, Conrad CH, Goldstein RH, and Bing OH. Transition from compensated hypertrophy to systolic heart failure in the spontaneously hypertensive rat: structure, function, and transcript analysis. Genomics 95: 84-92, 2010.
25. Cadalbert L, Sloss CM, Cameron P, and Plevin R. Conditional expression of MAP kinase phosphatase-2 protects against genotoxic stress-induced apoptosis by binding and selective dephosphorylation of nuclear activated c-jun Nterminal kinase. Cell Signal 17: 1254-1264, 2005.
26. Cadalbert LC, Sloss CM, Cunningham MR, Al-Mutairi M, McIntire A, Shipley J, and Plevin R. Differential regulation of MAP kinase activation by a novel splice variant of human MAP kinase phosphatase-2. Cell Signal 22: 357-365, 2010.
27. Cao S, Murphy BT, Foster C, Lazo JS, and Kingston DG. Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem 17: 2276-2281, 2009.
28. Cates CA, Michael RL, Stayrook KR, Harvey KA, Burke YD, Randall SK, Crowell PL, and Crowell DN. Prenylation of oncogenic human PTP(CAAX) protein tyrosine phosphatases. Cancer Lett 110: 49-55, 1996.
29. Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, and Ngan HY. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 29: 1742-1750, 2008.
30. Chen Y, Wang H, Zhang R, Peng Z, Sun R, and Tan Q. Microinjection of sanguinarine into the ventrolateral orbital cortex inhibits Mkp-1 and exerts an antidepressantlike effect in rats. Neurosci Lett 506: 327-331, 2012.
31. Chen YR, Han J, Kori R, Kong AN, and Tan TH. Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase. J Biol Chem 277: 39334-39342, 2002.
32. Chen YR, Shrivastava A, and Tan TH. Down-regulation of the c-Jun N-terminal kinase (JNK) phosphatase M3/6 and activation of JNK by hydrogen peroxide and pyrrolidine dithiocarbamate. Oncogene 20: 367-374, 2001.
33. Choi JC, Wu W, Muchir A, Iwata S, Homma S, and Worman HJ. Dual specificity phosphatase 4 mediates cardiomyopathy caused by lamin A/C (LMNA) gene mutation. J Biol Chem 287: 40513-40524, 2012.
34. Choi MS, Min SH, Jung H, Lee JD, Lee TH, Lee HK, and Yoo OJ. The essential role of FKBP38 in regulating phosphatase of regenerating liver 3 (PRL-3) protein stability. Biochem Biophys Res Commun 406: 305-309, 2011.
35. Choi SK, Oh HM, Lee SK, Jeong DG, Ryu SE, Son KH, Han DC, Sung ND, Baek NI, and Kwon BM. Biflavonoids inhibited phosphatase of regenerating liver-3 (PRL-3). Nat Prod Res 20: 341-346, 2006.
36. Chou LC, Chen CT, Lee JC, Way TD, Huang CH, Huang SM, Teng CM, Yamori T, Wu TS, Sun CM, Chien DS, Qian K, Morris-Natschke SL, Lee KH, Huang LJ, and Kuo SC. Synthesis and preclinical evaluations of 2-(2-fluorophenyl)-6,7- methylenedioxyquinolin-4-one monosodium phosphate (CHM-1-P-Na) as a potent antitumor agent. J Med Chem 53: 1616-1626, 2010.
37. Chugh R, Sangwan V, Patil SP, Dudeja V, Dawra RK, Banerjee S, Schumacher RJ, Blazar BR, Georg GI, Vickers SM, and Saluja AK. A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci Transl Med 4: 156ra139, 2012.
38. Cirit M, Grant KG, and Haugh JM. Systemic perturbation of the ERK signaling pathway by the proteasome inhibitor, MG132. PLoS One 7: e50975, 2012.
39. Clark AR, Martins JR, and Tchen CR. Role of dual specificity phosphatases in biological responses to glucocorticoids. J Biol Chem 283: 25765-25769, 2008.
40. Communal C, Colucci WS, Remondino A, Sawyer DB, Port JD, Wichman SE, Bristow MR, and Singh K. Reciprocal modulation of mitogen-activated protein kinases and mitogen-activated protein kinase phosphatase 1 and 2 in failing human myocardium. J Card Fail 8: 86-92, 2002.
41. Cornell TT, Fleszar A, McHugh W, Blatt NB, Le Vine AM, and Shanley TP. Mitogen-activated protein kinase phosphatase 2, MKP-2, regulates early inflammation in acute lung injury. Am J Physiol Lung Cell Mol Physiol 303: L251-L258, 2012.
42. Cornell TT, Rodenhouse P, Cai Q, Sun L, and Shanley TP. Mitogen-activated protein kinase phosphatase 2 regulates the inflammatory response in sepsis. Infect Immun 78: 2868-2876, 2010.
43. Cui Y, Parra I, Zhang M, Hilsenbeck SG, Tsimelzon A, Furukawa T, Horii A, Zhang ZY, Nicholson RI, and Fuqua SA. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res 66: 5950-5959, 2006.
44. Daouti S, Li WH, Qian H, Huang KS, Holmgren J, Levin W, Reik L, McGady DL, Gillespie P, Perrotta A, Bian H, Reidhaar-Olson JF, Bliss SA, Olivier AR, Sergi JA, Fry D, Danho W, Ritland S, Fotouhi N, Heimbrook D, and Niu H. A selective phosphatase of regenerating liver phosphatase inhibitor suppresses tumor cell anchorage-independent growth by a novel mechanism involving p130Cas cleavage. Cancer Res 68: 1162-1169, 2008.
45. den Hertog J, Groen A, and van der Wijk T. Redox regulation of protein-tyrosine phosphatases. Arch Biochem Biophys 434: 11-15, 2005.
46. Denu JM and Tanner KG. Specific and reversible inactivation of protein tyrosine phosphatases by hydrogen peroxide: evidence for a sulfenic acid intermediate and implications for redox regulation. Biochemistry 37: 5633-5642, 1998.
47. Diamond RH, Peters C, Jung SP, Greenbaum LE, Haber BA, Silberg DG, Traber PG, and Taub R. Expression of PRL-1 nuclear PTPase is associated with proliferation in liver but with differentiation in intestine. Am J Physiol 271: G121-G129, 1996.
48. Doddareddy MR, Rawling T, and Ammit AJ. Targeting mitogen-activated protein kinase phosphatase-1 (MKP-1): structure-based design of MKP-1 inhibitors and upregulators. Curr Med Chem 19: 163-173, 2012.
49. Domercq M, Alberdi E, Sánchez-Gómez MV, Ariz U, Pérez-Samartin A, and Matute C. Dual-specific phosphatase-6 (Dusp6) and ERK mediate AMPA receptor-induced oligodendrocyte death. J Biol Chem 286: 11825-11836, 2011.
50. Dong Y, Zhang L, Zhang S, Bai Y, Chen H, Sun X, Yong W, Li W, Colvin SC, Rhodes SJ, Shou W, and Zhang ZY. Phosphatase of regenerating liver 2 (PRL2) is essential for placental development by down-regulating PTEN (phosphatase and tensin homologue deleted on chromosome 10) and activating Akt protein. J Biol Chem 287: 32172-32179, 2012.
51. Doughty-Shenton D, Joseph JD, Zhang J, Pagliarini DJ, Kim Y, Lu D, Dixon JE, and Casey PJ. Pharmacological targeting of the mitochondrial phosphatase PTPMT1. J Pharmacol Exp Ther 333: 584-592, 2010.
52. Dumaual CM, Sandusky GE, Crowell PL, and Randall SK. Cellular localization of PRL-1 and PRL-2 gene expression in normal adult human tissues. J Histochem Cytochem 54: 1401-1412, 2006.
53. Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, Newton SS, and Duman RS. A negative regulator of MAP kinase causes depressive behavior. Nat Med 16: 1328-1332, 2010.
54. Emanuelli B, Eberle D, Suzuki R, and Kahn CR. Overexpression of the dual-specificity phosphatase MKP-4/DUSP-9 protects against stress-induced insulin resistance. Proc Natl Acad Sci USA 105: 3545-3550, 2008.
55. Feng B, Jiao P, Yang Z, and Xu H. MEK/ERK pathway mediates insulin-promoted degradation of MKP-3 protein in liver cells. Mol Cell Endocrinol 361: 116-123, 2012.
56. Forte E, Orsatti L, Talamo F, Barbato G, De Francesco R, and Tomei L. Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. Biochim Biophys Acta 1783: 334-344, 2008.
57. Furukawa T, Sunamura M, Motoi F, Matsuno S, and Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol 162: 1807-1815, 2003.
58. Galindo CL, Skinner MA, Errami M, Olson LD, Watson DA, Li J, McCormick JF, McIver LJ, Kumar NM, Pham TQ, and Garner HR. Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exerciseinduced cardiac hypertrophy and human cardiac failure. BMC Physiol 9: 23, 2009.
59. Gobert RP, Joubert L, Curchod ML, Salvat C, Foucault I, Jorand-Lebrun C, Lamarine M, Peixoto H, Vignaud C, Fremaux C, Jomotte T, Francon B, Alliod C, Bernasconi L, Abderrahim H, Perrin D, Bombrun A, Zanoguera F, Rommel C, and Hooft van Huijsduijnen R. Convergent functional genomics of oligodendrocyte differentiation identifies multiple autoinhibitory signaling circuits. Mol Cell Biol 29: 1538-1553, 2009.
60. Groen A, Lemeer S, van der Wijk T, Overvoorde J, Heck AJ, Ostman A, Barford D, Slijper M, and den Hertog J. Differential oxidation of protein-tyrosine phosphatases. J Biol Chem 280: 10298-10304, 2005.
61. Groschl B, Bettstetter M, Giedl C, Woenckhaus M, Edmonston T, Hofstadter F, and Dietmaier W. Expression of the MAP kinase phosphatase DUSP4 is associated with microsatellite instability in colorectal cancer (CRC) and causes increased cell proliferation. Int J Cancer 132: 1537-1546, 2013.
62. Guo K, Li J, Tang JP, Tan CP, Hong CW, Al-Aidaroos AQ, Varghese L, Huang C, and Zeng Q. Targeting intracellular oncoproteins with antibody therapy or vaccination. Sci Transl Med 3: 99ra85, 2011.
63. Guo K, Li J, Wang H, Osato M, Tang JP, Quah SY, Gan BQ, and Zeng Q. PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res 66: 9625-9635, 2006.
64. Guo K, Tang JP, Jie L, Al-Aidaroos AQ, Hong CW, Tan CP, Park JE, Varghese L, Feng Z, Zhou J, Chng WJ, and Zeng Q. Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice. Oncotarget 3: 158-171, 2012.
65. Guo K, Tang JP, Tan CP, Wang H, and Zeng Q. Monoclonal antibodies target intracellular PRL phosphatases to inhibit cancer metastases in mice. Cancer Biol Ther 7: 750-757, 2008.
66. Guzinska-Ustymowicz K and Pryczynicz A. PRL-3, an emerging marker of carcinogenesis, is strongly associated with poor prognosis. Anticancer Agents Med Chem 11: 99-108, 2011.
67. Gyorffy B, Surowiak P, Kiesslich O, Denkert C, Schafer R, Dietel M, and Lage H. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712, 2006.
68. Haagenson KK and Wu GS. The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment. Cancer Metastasis Rev 29: 143-149, 2010.
69. Halatsch ME, Low S, Mursch K, Hielscher T, Schmidt U, Unterberg A, Vougioukas VI, and Feuerhake F. Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation. J Neurosurg 111: 211-218, 2009.
70. Hamaguchi T, Sudo T, and Osada H. RK-682, a potent inhibitor of tyrosine phosphatase, arrested the mammalian cell cycle progression at G1phase. FEBS Lett 372: 54-58, 1995.
71. Han YM, Lee SK, Jeong DG, Ryu SE, Han DC, Kim DK, and Kwon BM. Emodin inhibits migration and invasion of DLD-1 (PRL-3) cells via inhibition of PRL-3 phosphatase activity. Bioorg Med Chem Lett 22: 323-326, 2012.
72. Haque A, Andersen JN, Salmeen A, Barford D, and Tonks NK. Conformation-sensing antibodies stabilize the oxidized form of PTP1B and inhibit its phosphatase activity. Cell 147: 185-198, 2011.
73. Hardy S, Wong NN, Muller WJ, Park M, and Tremblay ML. Overexpression of the protein tyrosine phosphatase PRL-2 correlates with breast tumor formation and progression. Cancer Res 70: 8959-8967, 2010.
74. Hasegawa T, Enomoto A, Kato T, Kawai K, Miyamoto R, Jijiwa M, Ichihara M, Ishida M, Asai N, Murakumo Y, Ohara K, Niwa Y, Goto H, and Takahashi M. Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice. Oncogene 27: 5684-5695, 2008.
75. He R, Zeng LF, He Y, Zhang S, and Zhang ZY. Small molecule tools for functional interrogation of protein tyrosine phosphatases. FEBS J 280: 731-750, 2013.
76. Heneberg P. Finding the smoking gun: protein tyrosine phosphatases as tools and targets of unicellular microorganisms and viruses. Curr Med Chem 19: 1530-1566, 2012.
77. Henkens R, Delvenne P, Arafa M, Moutschen M, Zeddou M, Tautz L, Boniver J, Mustelin T, and Rahmouni S. Cervix carcinoma is associated with an up-regulation and nuclear localization of the dual-specificity protein phosphatase VHR. BMC Cancer 8: 147, 2008.
78. Hirai G, Tsuchiya A, Koyama Y, Otani Y, Oonuma K, Dodo K, Simizu S, Osada H, and Sodeoka M. Development of a Vaccinia H1-related (VHR) phosphatase inhibitor with a nonacidic phosphate-mimicking core structure. Chem Med Chem 6: 617-622, 2011.
79. Hou N, Torii S, Saito N, Hosaka M, and Takeuchi T. Reactive oxygen species-mediated pancreatic beta-cell death is regulated by interactions between stress-activated protein kinases, p38 and c-Jun N-terminal kinase, and mitogen-activated protein kinase phosphatases. Endocrinology 149: 1654-1665, 2008.
80. Hoyt R, Zhu W, Cerignoli F, Alonso A, Mustelin T, and David M. Cutting edge: selective tyrosine dephosphorylation of interferon-activated nuclear STAT5 by the VHR phosphatase. J Immunol 179: 3402-3406, 2007.
81. Hu Y and Mivechi NF. Association and regulation of heat shock transcription factor 4b with both extracellular signal-regulated kinase mitogen-activated protein kinase and dual-specificity tyrosine phosphatase DUSP26. Mol Cell Biol 26: 3282-3294, 2006.
82. Huang CY, Lin YC, Hsiao WY, Liao FH, Huang PY, and Tan TH. DUSP4 deficiency enhances CD25 expression and CD4+ T-cell proliferation without impeding T-cell development. Eur J Immunol 42: 476-488, 2012.
83. Ishii T, Funato Y, andMiki H. Thioredoxin-related protein 32 (TRP32) specifically reduces oxidized phosphatase of regenerating liver (PRL). J Biol Chem288: 7263-7270, 2013.
84. Jeffrey KL, Brummer T, Rolph MS, Liu SM, Callejas NA, Grumont RJ, Gillieron C, Mackay F, Grey S, Camps M, Rommel C, Gerondakis SD, and Mackay CR. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol 7: 274-283, 2006.
85. Jeffrey KL, Camps M, Rommel C, and Mackay CR. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat Rev Drug Discov 6: 391-403, 2007.
86. Jeong DG, Kim SJ, Kim JH, Son JH, Park MR, Lim SM, Yoon TS, and Ryu SE. Trimeric structure of PRL-1 phosphatase reveals an active enzyme conformation and regulation mechanisms. J Mol Biol 345: 401-413, 2005.
87. Jiang ZX and Zhang ZY. Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev 27: 263-272, 2008.
88. Jiao P, Feng B, and Xu H. Mapping MKP-3/FOXO1 interaction and evaluating the effect on gluconeogenesis. PLoS One 7: e41168, 2012.
89. Jones RG and Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23: 537-548, 2009.
90. Kalkman HO. Potential opposite roles of the extracellular signal-regulated kinase (ERK) pathway in autism spectrum and bipolar disorders. Neurosci Biobehav Rev 36: 2206-2213, 2012.
91. Kamata H, Honda S, Maeda S, Chang L, Hirata H, and Karin M. Reactive oxygen species promote TNFa-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649-661, 2005.
92. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev 27: 253-261, 2008.
93. Kim HS, Ullevig SL, Zamora D, Lee CF, and Asmis R. Redox regulation of MAPK phosphatase 1 controls monocyte migration and macrophage recruitment. Proc Natl Acad Sci USA 109: E2803-E2812, 2012.
94. Kim JH, Cho H, Ryu SE, and Choi MU. Effects of metal ions on the activity of protein tyrosine phosphatase VHR: highly potent and reversible oxidative inactivation by Cu2 + ion. Arch Biochem Biophys 382: 72-80, 2000.
95. Kim KA, Song JS, Jee J, Sheen MR, Lee C, Lee TG, Ro S, Cho JM, Lee W, Yamazaki T, Jeon YH, and Cheong C. Structure of human PRL-3, the phosphatase associated with cancer metastasis. FEBS Lett 565: 181-187, 2004.
96. Kim SH, Shin SY, Lee KY, Joo EJ, Song JY, Ahn YM, Lee YH, and Kim YS. The genetic association of DUSP6 with bipolar disorder and its effect on ERK activity. Prog Neuropsychopharmacol Biol Psychiatry 37: 41-49, 2012.
97. Klinger S, Poussin C, Debril MB, Dolci W, Halban PA, and Thorens B. Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Diabetes 57: 584-593, 2008.
98. Konstantinopoulos PA, Karamouzis MV, and Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6: 541-555, 2007.
99. Kovanen PE, Bernard J, Al-Shami A, Liu C, Bollenbacher-Reilley J, Young L, Pise-Masison C, Spolski R, and Leonard WJ. T-cell development and function are modulated by dual specificity phosphatase DUSP5. J Biol Chem 283: 17362-17369, 2008.
100. Kozlov G, Cheng J, Ziomek E, Banville D, Gehring K, and Ekiel I. Structural insights into molecular function of the metastasis-associated phosphatase PRL-3. J Biol Chem 279: 11882-11889, 2004.
101. Kundu S, Fan K, Cao M, Lindner DJ, Tuthill R, Liu L, Gerson S, Borden E, and Yi T. Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics. Mol Cancer Ther 9: 2287-2296, 2010.
102. Kuznetsov VI, Hengge AC, and Johnson SJ. New aspects of the phosphatase VHZ revealed by a high-resolution structure with vanadate and substrate screening. Biochemistry 51: 9869-9879, 2012.
103. Lawan A, Al-Harthi S, Cadalbert L, McCluskey AG, Shweash M, Grassia G, Grant A, Boyd M, Currie S, and Plevin R. Deletion of the dual specific phosphatase-4 (DUSP-4) gene reveals an essential non-redundant role for MAP kinase phosphatase-2 (MKP-2) in proliferation and cell survival. J Biol Chem 286: 12933-12943, 2011.
104. Lawan A, Torrance E, Al-Harthi S, Shweash M, Alnasser S, Neamatallah T, Schroeder J, and Plevin R. MKP-2: out of the DUSP-bin and back into the limelight. Biochem Soc Trans 40: 235-239, 2012.
105. Lebrun AH, Moll-Khosrawi P, Pohl S, Makrypidi G, Storch S, Kilian D, Streichert T, Otto B, Mole SE, Ullrich K, Cotman S, Kohlschutter A, Braulke T, and Schulz A. Analysis of potential biomarkers and modifier genes affecting the clinical course of CLN3 disease. Mol Med 17: 1253-1261, 2011.
106. Lee JU, Huang S, Lee MH, Lee SE, Ryu MJ, Kim SJ, Kim YK, Kim SY, Joung KH, Kim JM, Shong M, and Jo YS. Dual specificity phosphatase 6 as a predictor of invasiveness in papillary thyroid cancer. Eur J Endocrinol 167: 93-101, 2012.
107. Levy-Nissenbaum O, Sagi-Assif O, Kapon D, Hantisteanu S, Burg T, Raanani P, Avigdor A, Ben-Bassat I, and Witz IP. Dual-specificity phosphatase Pyst2-L is constitutively highly expressed in myeloid leukemia and other malignant cells. Oncogene 22: 7649-7660, 2003.
108. Levy-Nissenbaum O, Sagi-Assif O, Raanani P, Avigdor A, Ben-Bassat I, and Witz IP. Overexpression of the dualspecificity MAPK phosphatase PYST2 in acute leukemia. Cancer Lett 199: 185-192, 2003.
109. Li G, Yu M, Lee WW, Tsang M, Krishnan E, Weyand CM, and Goronzy JJ. Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med 18: 1518-1524, 2012.
110. Lin FY, Chang CW, Cheong ML, Chen HC, Lee DY, Chang GD, and Chen H. Dual-specificity phosphatase 23 mediates GCM1 dephosphorylation and activation. Nucleic Acids Res 39: 848-861, 2011.
111. Lin NY, Lin CT, and Chang CJ. Modulation of immediate early gene expression by tristetraprolin in the differentiation of 3T3-L1 cells. Biochem Biophys Res Commun 365: 69-74, 2008.
112. Liu Q. Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 11: 377-383, 2011.
113. Liu RM, Choi J, Wu JH, Gaston Pravia KA, Lewis KM, Brand JD, Mochel NS, Krzywanski DM, Lambeth JD, Hagood JS, Forman HJ, Thannickal VJ, and Postlethwait EM. Oxidative modification of nuclear mitogen-activated protein kinase phosphatase 1 is involved in transforming growth factor beta1-induced expression of plasminogen activator inhibitor 1 in fibroblasts. J Biol Chem 285: 16239-16247, 2010.
114. Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ, Su WW, and Hu RM. Increased expression of PRL-1 protein correlates with shortened patient survival in human hepatocellular carcinoma. Clin Transl Oncol 14: 287-293, 2012.
115. Luo LJ, Liu F, Wang XY, Dai TY, Dai YL, Dong C, and Ge BX. An essential function for MKP5 in the formation of oxidized low density lipid-induced foam cells. Cell Signal 24: 1889-1898, 2012.
116. Lv J, Liu C, Huang H, Meng L, Jiang B, Cao Y, Zhou Z, She T, Qu L, Wei Song S, and Shou C. Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3. Gene Ther [Epub ahead of print]; DOI: 10.1038/gt.2013.5, 2013.
117. Marti F, Krause A, Post NH, Lyddane C, Dupont B, Sadelain M, and King PD. Negative-feedback regulation of CD28 costimulation by a novel mitogen-activated protein kinase phosphatase, MKP6. J Immunol 166: 197-206, 2001.
118. Matter WF, Estridge T, Zhang C, Belagaje R, Stancato L, Dixon J, Johnson B, Bloem L, Pickard T, Donaghue M, Acton S, Jeyaseelan R, Kadambi V, and Vlahos CJ. Role of PRL-3, a human muscle-specific tyrosine phosphatase, in angiotensin-II signaling. Biochem Biophys Res Commun 283: 1061-1068, 2001.
119. McParland V, Varsano G, Li X, Thornton J, Baby J, Aravind A, Meyer C, Pavic K, Ŕos P, and Köhn M. The metastasis-promoting phosphatase PRL-3 shows activity toward phosphoinositides. Biochemistry 50: 7579-7590, 2011.
120. Messina S, Frati L, Leonetti C, Zuchegna C, Di Zazzo E, Calogero A, and Porcellini A. Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. Oncogene 30: 3813-3820, 2011.
121. Min G, Lee SK, Kim HN, Han YM, Lee RH, Jeong DG, Han DC, and Kwon BM. Rhodanine-based PRL-3 inhibitors blocked the migration and invasion of metastatic cancer cells. Bioorg Med Chem Lett 23: 3769-3774, 2013.
122. Mocanu MM and Yellon DM. PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury? Br J Pharmacol 150: 833-838, 2007.
123. Molina G, Vogt A, Bakan A, Dai W, Queiroz de Oliveira P, Znosko W, Smithgall TE, Bahar I, Lazo JS, Day BW, and Tsang M. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat Chem Biol 5: 680-687, 2009.
124. Moon MK, Han YM, Lee YJ, Lee LH, Yang JH, Kwon BM, and Kim DK. Inhibitory activities of anthraquinones from Rubia akane on phosphatase regenerating liver-3. Arch Pharm Res 33: 1747-1751, 2010.
125. Mori Sequeiros Garcia M, Gomez NV, Gorostizaga A, Acquier A, Gonzalez-Calvar SI, Mendez CF, and Paz C. MAP kinase phosphatase-3 (MKP-3) is transcriptionally and post-translationally up-regulated by hCG and modulates cAMP-induced p21 expression in MA-10 Leydig cells. Mol Cell Endocrinol 371: 174-181, 2013.
126. Mukherjee A and Martin SG. The thioredoxin system: a key target in tumour and endothelial cells. Br J Radiol 81 Spec No 1: S57-S68, 2008.
127. Niemi NM, Lanning NJ, Westrate LM, and MacKeigan JP. Downregulation of the mitochondrial phosphatase PTPMT1 is sufficient to promote cancer cell death. PLoS One 8: e53803, 2013.
128. Nunes-Xavier C, Romá-Mateo C, Ŕos P, Tarréga C, Cejudo-Maŕn R, Tabernero L, and Pulido R. Dual-specificity MAP kinase phosphatases as targets of cancer treatment. Anticancer Agents Med Chem 11: 109-132, 2011.
129. Okami N, Narasimhan P, Yoshioka H, Sakata H, Kim GS, Jung JE, Maier CM, and Chan PH. Prevention of JNK phosphorylation as a mechanism for rosiglitazone in neuroprotection after transient cerebral ischemia: activation of dual specificity phosphatase. J Cereb Blood Flow Metab 33: 106-114, 2013.
130. Owens DM and Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26: 3203-3213, 2007.
131. Pagarigan KT, Bunn BW, Goodchild J, Rahe TK, Weis JF, and Saucedo LJ. Drosophila PRL-1 is a growth inhibitor that counteracts the function of the Src oncogene. PLoS One 8: e61084, 2013.
132. Pagliarini DJ, Wiley SE, Kimple ME, Dixon JR, Kelly P, Worby CA, Casey PJ, and Dixon JE. Involvement of a mitochondrial phosphatase in the regulation of ATP production and insulin secretion in pancreatic beta cells. Mol Cell 19: 197-207, 2005.
133. Park H, Jeon JY, and Ryu ER. Virtual screening and biochemical evaluation of mitogen-activated protein kinase phosphatase 4 inhibitors. Bull. Korean Chem. Soc. 33: 3772-3776, 2012.
134. Park H, Jung SK, Jeong DG, Ryu SE, and Kim SJ. Discovery of novel PRL-3 inhibitors based on the structurebased virtual screening. Bioorg Med Chem Lett 18: 2250-2255, 2008.
135. Park H, Kim SY, Kyung A, Yoon TS, Ryu SE, and Jeong DG. Structure-based virtual screening approach to the discovery of novel PTPMT1 phosphatase inhibitors. Bioorg Med Chem Lett 22: 1271-1275, 2012.
136. Park JE, Park BC, Song M, Park SG, Lee do H, Park SY, Kim JH, and Cho S. PTP inhibitor IV protects JNK kinase activity by inhibiting dual-specificity phosphatase 14 (DUSP14). Biochem Biophys Res Commun 387: 795-799, 2009.
137. Pathak MK, Dhawan D, Lindner DJ, Borden EC, Farver C, and Yi T. Pentamidine is an inhibitor of PRL phos-phatases with anticancer activity. Mol Cancer Ther 1: 1255-1264, 2002.
138. Patterson KI, Brummer T, O'Brien PM, and Daly RJ. Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem J 418: 475-489, 2009.
139. Pennington JD, Jacobs KM, Sun L, Bar-Sela G, Mishra M, and Gius D. Thioredoxin and thioredoxin reductase as redox-sensitive molecular targets for cancer therapy. Curr Pharm Des 13: 3368-3377, 2007.
140. Powis G and Kirkpatrick DL. Thioredoxin signaling as a target for cancer therapy. Curr Opin Pharmacol 7: 392-397, 2007.
141. Pulido R and Hooft van Huijsduijnen R. Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease. FEBS J 275: 848-866, 2008.
142. Qian F, Deng J, Cheng N, Welch EJ, Zhang Y, Malik AB, Flavell RA, Dong C, and Ye RD. A non-redundant role for MKP5 in limiting ROS production and preventing LPS-induced vascular injury. EMBO J 28: 2896-2907, 2009.
143. Rahmouni S, Cerignoli F, Alonso A, Tsutji T, Henkens R, Zhu C, Louis-dit-Sully C, Moutschen M, Jiang W, and Mustelin T. Loss of the VHR dual-specific phosphatase causes cell-cycle arrest and senescence. Nat Cell Biol 8: 524-531, 2006.
144. Ralph JA and Morand EF. MAPK phosphatases as novel targets for rheumatoid arthritis. Expert Opin Ther Targets 12: 795-808, 2008.
145. Ŕos P, Li X, and Köhn M. Molecular mechanisms of the PRL phosphatases. FEBS J 280: 505-524, 2013.
146. Romá-Mateo C, Ŕos P, Tabernero L, Attwood TK, and Pulido R. A novel phosphatase family, structurally related to dual-specificity phosphatases, that displays unique amino acid sequence and substrate specificity. J Mol Biol 374: 899-909, 2007.
147. Romá-Mateo C, Sacristán-Reviriego A, Beresford NJ, Caparrós-Martin JA, Culiáñez-Macià FA, Mart́n H, Molina M, Tabernero L, and Pulido R. Phylogenetic and genetic linkage between novel atypical dual-specificity phosphatases from non-metazoan organisms. Mol Genet Genomics 285: 341-354, 2011.
148. Ross SH, Lindsay Y, Safrany ST, Lorenzo O, Villa F, Toth R, Clague MJ, Downes CP, and Leslie NR. Differential redox regulation within the PTP superfamily. Cell Signal 19: 1521-1530, 2007.
149. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St. Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, and Vogelstein B. A phosphatase associated with metastasis of colorectal cancer. Science 294: 1343-1346, 2001.
150. Salojin K and Oravecz T. Regulation of innate immunity by MAPK dual-specificity phosphatases: knockout models reveal new tricks of old genes. J Leukoc Biol 81: 860-869, 2007.
151. Schmidt F, van den Eijnden M, Pescini Gobert R, Saborio GP, Carboni S, Alliod C, Pouly S, Staugaitis SM, Dutta R, Trapp B, and Hooft van Huijsduijnen R. Identification of VHY/Dusp15 as a regulator of oligodendrocyte differentiation through a systematic genomics approach. PLoS One 7: e40457, 2012.
152. Schories B, Janz M, Dorken B, and Bommert K. Downregulation of genes involved in DNA repair and differential expression of transcription regulators and phosphatases precede IgM-induced apoptosis in the Burkitt's lymphoma cell line BL60-BL62. Biochim Biophys Acta 1676: 83-95, 2004.
153. Scott LM, Lawrence HR, Sebti SM, Lawrence NJ, and Wu J. Targeting protein tyrosine phosphatases for anticancer drug discovery. Curr Pharm Des 16: 1843-1862, 2010.
154. Seo H and Cho S. Specific inhibition of DUSP14 by NSC-95397 in vitro. Bull Korean Chem Soc 32: 4435-4437, 2011.
155. Shen J, Chandrasekharan UM, Ashraf MZ, Long E, Morton RE, Liu Y, Smith JD, and DiCorleto PE. Lack of mitogen-activated protein kinase phosphatase-1 protects ApoE-null mice against atherosclerosis. Circ Res 106: 902-910, 2010.
156. Shen J, Liu X, Yu WM, Liu J, Nibbelink MG, Guo C, Finkel T, and Qu CK. A critical role of mitochondrial phosphatase Ptpmt1 in embryogenesis reveals a mitochondrial metabolic stress-induced differentiation checkpoint in embryonic stem cells. Mol Cell Biol 31: 4902-4916, 2011.
157. Shin DY, Ishibashi T, Choi TS, Chung E, Chung IY, Aaronson SA, and Bottaro DP. A novel human ERK phosphatase regulates H-ras and v-raf signal transduction. Oncogene 14: 2633-2639, 1997.
158. Shin SH, Park SY, and Kang GH. Down-regulation of dual-specificity phosphatase 5 in gastric cancer by promoter CpG island hypermethylation and its potential role in carcinogenesis. Am J Pathol 182: 1275-1285, 2013.
159. Shin Y, Kim GD, Jeon JE, Shin J, and Lee SK. Antimetastatic effect of halichondramide, a trisoxazole macrolide from the marine sponge chondrosia corticata, on human prostate cancer cells via modulation of epithelialto- mesenchymal transition. Mar Drugs 11: 2472-2485, 2013.
160. Skinner AL, Vartia AA, Williams TD, and Laurence JS. Enzyme activity of phosphatase of regenerating liver is controlled by the redox environment and its C-terminal residues. Biochemistry 48: 4262-4272, 2009.
161. Song M, Park JE, Park SG, Lee do H, Choi HK, Park BC, Ryu SE, Kim JH, and Cho S. NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun 381: 491-495, 2009.
162. Sun JP, Wang WQ, Yang H, Liu S, Liang F, Fedorov AA, Almo SC, and Zhang ZY. Structure and biochemical properties of PRL-1, a phosphatase implicated in cell growth, differentiation, and tumor invasion. Biochemistry 44: 12009-12021, 2005.
163. Sun ZH and Bu P. Downregulation of phosphatase of regenerating liver-3 is involved in the inhibition of proliferation and apoptosis induced by emodin in the SGC-7901 human gastric carcinoma cell line. Exp Ther Med 3: 1077-1081, 2012.
164. Tang JP, Tan CP, Li J, Siddique MM, Guo K, Chan SW, Park JE, Tay WN, Huang ZY, Li WC, Chen J, and Zeng Q. VHZ is a novel centrosomal phosphatase associated with cell growth and human primary cancers. Mol Cancer 9: 128, 2010.
165. Tanner JJ, Parsons ZD, Cummings AH, Zhou H, and Gates KS. Redox regulation of protein tyrosine phosphatases: structural and chemical aspects. Antioxid Redox Signal 15: 77-97, 2011.
166. Theodosiou A and Ashworth A. Differential effects of stress stimuli on a JNK-inactivating phosphatase. Oncogene 21: 2387-2397, 2002.
167. Thiriet N, Humblot N, Burgun C, Aunis D, and Zwiller J. Cocaine and fluoxetine induce the expression of the hVH-5 gene encoding a MAP kinase phosphatase. Brain Res Mol Brain Res 62: 150-157, 1998.
168. Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. Cell 121: 667-670, 2005.
169. Tonks NK and Muthuswamy SK. A brake becomes an accelerator: PTP1B-a new therapeutic target for breast cancer. Cancer Cell 11: 214-216, 2007.
170. Turner-Ivey B, Manevich Y, Schulte J, Kistner-Griffin E, Jezierska-Drutel A, Liu Y, and Neumann CA. Role for Prdx1 as a specific sensor in redox-regulated senescence in breast cancer. Oncogene [Epub ahead of print]; DOI: 10.1038/onc.2012.624, 2013.
171. Ueda K, Arakawa H, and Nakamura Y. Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. Oncogene 22: 5586-5591, 2003.
172. Vogt A, Cooley KA, Brisson M, Tarpley MG, Wipf P, and Lazo JS. Cell-active dual specificity phosphatase inhibitors identified by high-content screening. Chem Biol 10: 733-742, 2003.
173. Vogt A, McDonald PR, Tamewitz A, Sikorski RP, Wipf P, Skoko JJ, 3rd, and Lazo JS. A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells. Mol Cancer Ther 7: 330-340, 2008.
174. Vogt A, Tamewitz A, Skoko J, Sikorski RP, Giuliano KA, and Lazo JS. The benzo[c]phenanthridine alkaloid, sanguinarine, is a selective, cell-active inhibitor of mitogenactivated protein kinase phosphatase-1. J Biol Chem 280: 19078-19086, 2005.
175. Vu HN, Miller WJ, O'Connor SA, He M, Schafer PH, Payvandi F, Muller GW, Stirling DI, and Libutti SK. CC-5079: a small molecule with MKP1, antiangiogenic, and antitumor activity. J Surg Res 164: 116-125, 2010.
176. Wancket LM, Frazier WJ, and Liu Y. Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci 90: 237-248, 2012.
177. Wang H, Quah SY, Dong JM, Manser E, Tang JP, and Zeng Q. PRL-3 down-regulates PTEN expression and signals through PI3K to promote epithelial-mesenchymal transition. Cancer Res 67: 2922-2926, 2007.
178. Wang J, Kirby CE, and Herbst R. The tyrosine phosphatase PRL-1 localizes to the endoplasmic reticulum and the mitotic spindle and is required for normal mitosis. J Biol Chem 277: 46659-46668, 2002.
179. Wang JY, Lin CH, Yang CH, Tan TH, and Chen YR. Biochemical and biological characterization of a neuroendocrine-associated phosphatase. J Neurochem 98: 89-101, 2006.
180. Wang JY, Yang CH, Yeh CL, Lin CH, and Chen YR. NEAP causes down-regulation of EGFR, subsequently induces the suppression of NGF-induced differentiation in PC12 cells. J Neurochem 107: 1544-1555, 2008.
181. Wang JY, Yeh CL, Chou HC, Yang CH, Fu YN, Chen YT, Cheng HW, Huang CY, Liu HP, Huang SF, and Chen YR. Vaccinia H1-related phosphatase is a phosphatase of ErbB receptors and is down-regulated in non-small cell lung cancer. J Biol Chem 286: 10177-10184, 2011.
182. Wang L, Shen Y, Song R, Sun Y, Xu J, and Xu Q. An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol Pharmacol 76: 1238-1245, 2009.
183. Wang Y and Lazo JS. Metastasis-associated phosphatase PRL-2 regulates tumor cell migration and invasion. Oncogene 31: 818-827, 2012.
184. Wei W, Jiao Y, Postlethwaite A, Stuart JM, Wang Y, Sun D, and Gu W. Dual-specificity phosphatases 2: surprising positive effect at the molecular level and a potential biomarker of diseases. Genes Immun 14: 1-6, 2013.
185. Wentworth CC, Alam A, Jones RM, Nusrat A, and Neish AS. Enteric commensal bacteria induce extracellular signal-regulated kinase pathway signaling via formyl peptide receptor-dependent redox modulation of dual specific phosphatase 3. J Biol Chem 286: 38448-38455, 2011.
186. Wilson WR and Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 11: 393-410, 2011.
187. Wishart MJ and Dixon JE. PTEN and myotubularin phosphatases: from 3-phosphoinositide dephosphorylation to disease. Trends Cell Biol 12: 579-585, 2002.
188. Wong VC, Chen H, Ko JM, Chan KW, Chan YP, Law S, Chua D, Kwong DL, Lung HL, Srivastava G, Tang JC, Tsao SW, Zabarovsky ER, Stanbridge EJ, and Lung ML. Tumor suppressor dual-specificity phosphatase 6 (DUSP6) impairs cell invasion and epithelial-mesenchymal transition (EMT)-associated phenotype. Int J Cancer 130: 83-95, 2012.
189. Wu GS. Role of mitogen-activated protein kinase phosphatases (MKPs) in cancer. Cancer Metastasis Rev 26: 579-585, 2007.
190. Wu J, Jin YJ, Calaf GM, Huang WL, and Yin Y. PAC1 is a direct transcription target of E2F-1 in apoptotic signaling. Oncogene 26: 6526-6535, 2007.
191. Wu JJ, Roth RJ, Anderson EJ, Hong EG, Lee MK, Choi CS, Neufer PD, Shulman GI, Kim JK, and Bennett AM. Mice lacking MAP kinase phosphatase-1 have enhanced MAP kinase activity and resistance to diet-induced obesity. Cell Metab 4: 61-73, 2006.
192. Wu S, Vossius S, Rahmouni S, Miletic AV, Vang T, Vazquez-Rodriguez J, Cerignoli F, Arimura Y, Williams S, Hayes T, Moutschen M, Vasile S, Pellecchia M, Mustelin T, and Tautz L. Multidentate small-molecule inhibitors of vaccinia H1-related (VHR) phosphatase decrease proliferation of cervix cancer cells. J Med Chem 52: 6716-6723, 2009.
193. Wu Z, Jiao P, Huang X, Feng B, Feng Y, Yang S, Hwang P, Du J, Nie Y, Xiao G, and Xu H. MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice. J Clin Invest 120: 3901-3911, 2010.
194. Xiao Y, Yeong Chit Chia J, Gajewski JE, Sio Seng Lio D, Mulhern TD, Zhu HJ, Nandurkar H, and Cheng HC. PTEN catalysis of phospholipid dephosphorylation reaction follows a two-step mechanism in which the conserved aspartate-92 does not function as the general acid-mechanistic analysis of a familial Cowden disease-associated PTEN mutation. Cell Signal 19: 1434-1445, 2007.
195. Xu H, Dembski M, Yang Q, Yang D, Moriarty A, Tayber O, Chen H, Kapeller R, and Tartaglia LA. Dual specificity mitogen-activated protein (MAP) kinase phosphatase-4 plays a potential role in insulin resistance. J Biol Chem 278: 30187-30192, 2003.
196. Xu LG, Wu M, Hu J, Zhai Z, and Shu HB. Identification of downstream genes up-regulated by the tumor necrosis factor family member TALL-1. J Leukoc Biol 72: 410-416, 2002.
197. Yang D, Xie P, and Liu Z. Ischemia/reperfusion-induced MKP-3 impairs endothelial NO formation via inactivation of ERK1/2 pathway. PLoS One 7: e42076, 2012.
198. Yin Y, Liu YX, Jin YJ, Hall EJ, and Barrett JC. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature 422: 527-531, 2003.
199. Yu M, Li G, Lee WW, Yuan M, Cui D, Weyand CM, and Goronzy JJ. Signal inhibition by the dual-specific phosphatase 4 impairs T cell-dependent B-cell responses with age. Proc Natl Acad Sci USA 109: E879-E888, 2012.
200. Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, Pallen CJ, Manser E, and Hong W. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res 63: 2716-2722, 2003.
201. Zeng Q, Si X, Horstmann H, Xu Y, Hong W, and Pallen CJ. Prenylation-dependent association of protein-tyrosine phosphatases PRL-1,-2, and-3 with the plasma membrane and the early endosome. J Biol Chem 275: 21444-21452, 2000.
202. Zhang J, Guan Z, Murphy AN, Wiley SE, Perkins GA, Worby CA, Engel JL, Heacock P, Nguyen OK, Wang JH, Raetz CR, Dowhan W, and Dixon JE. Mitochondrial phosphatase PTPMT1 is essential for cardiolipin biosynthesis. Cell Metab 13: 690-700, 2011.
203. Zhang Y, Blattman JN, Kennedy NJ, Duong J, Nguyen T, Wang Y, Davis RJ, Greenberg PD, Flavell RA, and Dong C. Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature 430: 793-797, 2004.
204. Zhao M. PTEN: a promising pharmacological target to enhance epithelial wound healing. Br J Pharmacol 152: 1141-1144, 2007.
205. Zheng H, Li Q, Chen R, Zhang J, Ran Y, He X, Li S, and Shu HB. The dual-specificity phosphatase DUSP14 negatively regulates tumor necrosis factor-and interleukin-1-induced nuclear factor-kappaB activation by dephosphorylating the protein kinase TAK1. J Biol Chem 288: 819-825, 2013.
206. ZhuQY, LiuQ,Chen JX, LanK, andGeBX.MicroRNA-101 targets MAPK phosphatase-1 to regulate the activation of MAPKs in macrophages. J Immunol 185: 7435-7442, 2010.
207. Zimmerman MW, Homanics GE, and Lazo JS. Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS One 8: e58300, 2013.